title: Part III: cutaneous hypersensitivity during selective serotonin reuptake inhibitor therapy resulting in acquired cutis laxa.
authors.affiliation: Brigham and Women's Hospital, Department of Dermatology, Harvard Medical School, Boston, MA, USA.
authors.forename: Jennifer K
authors.initials: JK
authors.lastname: Tan
authors.forename: Adam D
authors.initials: AD
authors.lastname: Lipworth
authors.forename: Andrew A
authors.initials: AA
authors.lastname: Nelson
authors.forename: Artur
authors.initials: A
authors.lastname: Zembowicz
authors.forename: Samuel L
authors.initials: SL
authors.lastname: Moschella
mesh_terms: D000328:Adult; D015283:Citalopram / Q000009:adverse effects* / Q000627:therapeutic use; D003483:Cutis Laxa / Q000139:chemically induced* / Q000188:drug therapy*; D003876:Dermatitis, Atopic / Q000139:chemically induced* / Q000188:drug therapy; D005260:Female; D006801:Humans; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D012867:Skin / Q000473:pathology*
chemical_list: D015283:Citalopram; D017367:Selective Serotonin Reuptake Inhibitors